Preventive health intelligence company

Healthcare treats chronic disease downstream. We bring intelligence upstream.

UPSTRIQ™ HEALTH is building the missing layer in healthcare.

The path to chronic disease

The detection window moves earlier.

  1. Upstream driversemotional · stress · sleep
  2. UPSTRIQ™ intended detection window
  3. Allostatic loadcumulative wear and tear
  4. Chronic inflammationpersistent, low-grade
  5. Chronic diseasemental · cardiometabolic · neurodevelopmental · cognitive · inflammatoryToday: detected at diagnosis

Conceptual

We apply AI and machine learning to upstream drivers of health, passive data and clinical data to develop digital biomarkers and disease-specific risk forecasts across mental health, cardiometabolic, neurodevelopmental, cognitive and inflammatory conditions.

See what's upstream. Shape what's downstream.

The unmet need

Health changes before diagnosis and between visits, and is often measured too late.

Healthcare today is built to react. It responds once symptoms manifest, thresholds are crossed and damage is harder to reverse, because that is when the available measures show up. Clinicians act on what they can see. We help them see more, earlier.

Between visits

Visits are snapshots

Most health data is captured in short appointments. What happens in the days and weeks between goes unseen.

Before diagnosis

Drivers shift first

Sleep, stress, connection and other upstream drivers change well before a condition is named.

After diagnosis

Treatment follows

By the time a condition is named, the response is managing it, often with medication, when there is less room to change course.

Missed early

Conditions often go unrecognized or untreated for a long time.

Prediabetes

80%

8 in 10 adults with prediabetes do not know they have it[1].

Mental health

50%

1 in 2 adults with a mental illness received no mental health treatment in the past year (2022)[2].

Time to care

6 to 8

years between first onset of a mood disorder and first treatment contact, among people who eventually seek care (2005 national survey)[3].

The burden

90% of U.S. health care spending goes to people with chronic and mental health conditions.

If much of this disease can be changed earlier, the spending that follows it is the price of waiting.

The cost

What chronic and mental health conditions cost the U.S. system.

2024actual

$5.3T[4]

About $4.8T is for people with chronic and mental health conditions[5].

2034projected

Nearly $9T[6]

About $8T if the 90% share holds.

62% rise in U.S. health spending in the decade to 2022[7].

Chronic and mental health conditions All other spending Projection

How common

How many people it reaches.

Chronic disease

Most U.S. adults have at least one.

6 in 10

U.S. adults live with a chronic disease. 4 in 10 have two or more[8].
Inflammation

Driven by persistent, low-grade inflammation.

50%+

of all deaths are attributable to inflammation-related diseases[9].
Stress and burnout

Chronic stress that outruns recovery.

76%

of full-time employees feel burned out at times; 28% often or always (2018 survey)[10].

By condition

Where it concentrates.

Mental health

Depression, anxiety, ADHD-related functioning, perinatal.

59.3M

U.S. adults (23.1%) had a mental illness in 2022[2].
Cardiometabolic

Hypertension, heart failure, stroke, type 2 diabetes, obesity, fatty liver.

115.2M

U.S. adults, more than 2 in 5, have prediabetes[1].

Annual health care costs of cardiovascular conditions are projected to nearly quadruple, from $393B in 2020 to $1.49T in 2050, inflation-adjusted[7].

Cognition and aging

Development, mild impairment and dementia; healthy aging, frailty and loss of reserve.

7.2M

Americans 65 and older have Alzheimer's dementia, 12.7M by 2050. Care costs $384B in 2025 and nearly $1T by 2050[11].

1 in 5 Americans will be 65 or older by 2030[12].

The UPSTRIQ solution

Earlier insight, starting with five areas of chronic disease and health.

UPSTRIQ™ Health is building a proprietary preventive health intelligence layer. Applied across these areas, our digital biomarkers and AI-powered predictive analytics are designed to forecast emerging risk and connect people to earlier intervention before disease develops or chronic illness worsens. These are our first areas of focus, and the same platform extends to other chronic conditions. Each follows the same pattern, where upstream drivers become signals, signals become forecasts and forecasts lead to earlier action.

Mental health intelligence

Identify changes in behavioral and daily-life signals that may indicate emerging mental health risk, supporting earlier assessment and intervention.

Cardiometabolic health

Connect upstream drivers with physiological and clinical signals to identify emerging cardiometabolic risk and inform preventive action.

Cognitive resilience

Track changes in cognitive and behavioral patterns to help identify emerging concerns and support earlier evaluation.

Inflammatory health

Integrate daily-life and clinical data to investigate patterns associated with inflammation and inform earlier risk assessment.

Neurodevelopmental health

Explore patterns in attention, sleep, behavior and daily functioning to better understand individual needs and support earlier assessment and personalized care.

Tailwinds

Three tailwinds are lining up behind prevention.

Devices

About 91% of U.S. adults own a smartphone; nearly a third track health with a wearable.[13][14]

Data access

Connected clinical data under federal interoperability rules.[15]

Payment

Prevention and value-based care, including CMS's goal of accountable care for all Traditional Medicare beneficiaries by 2030.[16]

Scale and impact

Built for scale, impact and interoperability.

Our platform bridges the gap between fragmented health data and actionable clinical foresight. By meeting the rigorous validation standards required by federal health innovation initiatives, UPSTRIQ™ delivers scalable solutions designed to eliminate health disparities and protect populations at scale.

“We aren’t just predicting the future of health. We are giving individuals and healthcare systems the window of time needed to change it.”Shilpa Parikh, MBA · Founder & CEO, UPSTRIQ™ HEALTH
Why UPSTRIQ

Connecting data to deliver validated forecasts for real value.

Assessments, wearables and clinical risk tools each see one part, often once disease is underway. UPSTRIQ is designed to connect all three over time.

Trust and fit

Clinically validated

Every measure, biomarker and model is validated for its intended population and use.

Hardware & system agnostic

Complements the devices and systems customers already use, and exchanges data with them in both directions via API.

Who benefits

Patient outcomes

Earlier action on emerging risk, before disease develops, function declines or chronic illness worsens.

Enterprise value

Upstream health insight for employers, universities and programs, with participant tracking and de-identified reporting.

Payer savings

Designed to lower costs by moving intervention upstream of acute care and costly complications.

The first validation study, ASPEN™, is in process.

Sources & references

Sources & references.

  1. CDC. Prediabetes: Could It Be You? Updated February 2026. cdc.gov ↗
  2. NIMH. Mental illness statistics, 2022 data. nimh.nih.gov ↗
  3. Wang PS, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005;62:603-613. hms.harvard.edu ↗
  4. CMS. National Health Expenditure Data, historical (2024: $5.3 trillion). cms.gov ↗
  5. CDC. Fast Facts: Health and Economic Costs of Chronic Conditions. Reviewed May 2026. cdc.gov ↗
  6. CMS Office of the Actuary. National Health Expenditure Projections, 2025 to 2034. cms.gov ↗
  7. American Heart Association. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory. Circulation, 2024. ahajournals.org ↗
  8. CDC. Chronic Diseases in America (accessed Oct 2026). cdc.gov ↗
  9. Furman D, et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 2019. nature.com ↗
  10. Gallup, 2018. Employee burnout: causes and cures. gallup.com ↗
  11. Alzheimer's Association. 2025 Alzheimer's Disease Facts and Figures. alz.org ↗
  12. U.S. Census Bureau, 2018. Older people projected to outnumber children by 2035. census.gov ↗
  13. Pew Research Center. Mobile Fact Sheet. Survey January–June 2026. pewresearch.org ↗
  14. NHLBI. Study reveals wearable device trends among U.S. adults (HINTS). June 2023. nhlbi.nih.gov ↗
  15. ONC. The Cures Act Final Rule: interoperability-focused policies. 2020. healthit.gov ↗
  16. CMS. CMS moves closer to accountable care goals with 2025 ACO initiatives. January 2025. cms.gov ↗
UPSTRIQ / Science Science

The science behind upstream health.

Chronic disease leaves footprints years before diagnosis. We measure and learn from them.

Conceptual · not patient data

Sleep that stops restoring. Stress that stops resetting. Connection that thins. While each is small alone, when measured together over time they may be used to forecast risk of chronic disease, perhaps early enough to intervene and change the trajectory. We are validating to earn each claim.

The biology of disease

From upstream stressors to chronic disease.

Repeated stress can build allostatic load and chronic inflammation, linked to many chronic diseases. UPSTRIQ™ measures at the first step.

1 · Upstream

Stressors

  • Chronic stress
  • Poor sleep
  • Social isolation
  • Digital overload
  • Environment
  • Diet and inactivity
  • Substances
2 · Stress response

HPA axis + SNS

  1. Hypothalamus
  2. CRH
  3. Pituitary
  4. ACTH, in the blood
  5. Adrenal glandsCortisol

Sympathetic nerves Adrenaline

Cortisol feedback, weakened by chronic stress

3 · Load & capacity*

Load builds,
capacity wears down

Building Burden

Neuroendocrine

Cortisol · DHEA-S (low) · Adrenaline

Cardiovascular

Systolic BP · Diastolic BP

Metabolic

HbA1c · Waist-to-hip ratio · HDL (low)

* MacArthur markers. Examples, not a full panel.

4 · Inflammation

Chronic, low‑grade
inflammation

  • CRP ↑
  • IL-6 ↑
  • TNF-α ↑

Immune cells stop responding to cortisol (glucocorticoid resistance)

5 · Outcome

Chronic diseases

  • Mental health
  • Cardiometabolic
  • Neurodevelopmental
  • Aging & cognition
  • Inflammatory

UPSTRIQ™ starts measuring here

Research panels,
once, at a visit

Simplified schematic, not a fixed sequence. Stressors do not necessarily progress to each condition shown. Based on McEwen 1998; Slavich and Irwin 2014; Cohen et al. 2012; Furman et al. 2019. Read the allostatic load primer →
Allostatic load

Four ways load builds.

Allostatic load is the wear and tear when the body's stress adjustments are demanded too often or last too long (McEwen, 1998).

Repeated hits

Frequent stressors, no recovery between.

No adaptation

A full reaction to the same stressor, every time.

Prolonged response

The response does not shut off when the stressor ends.

Inadequate response

Too little cortisol, so inflammation overreacts.

How it is measured in research

Ten markers, one score.

The MacArthur studies combined ten markers into one score (Seeman et al., 1997); later work adds CRP and IL-6.

  • Systolic BP
  • Diastolic BP
  • Waist-to-hip ratio
  • HDL cholesterol
  • Total/HDL ratio
  • HbA1c
  • Cortisol
  • Epinephrine
  • Norepinephrine
  • DHEA-S

These panels are one-time snapshots. Our candidate MUDH™ Biomarkers for Load, Recovery and Capacity aim to track strain and recovery continuously, and will be tested against an independent clinical reference.

MUDH™ Signals & MUDH™ Biomarkers science

Load, recovery & adaptive capacity.

LOAD

The strain carried: stress, poor sleep, isolation, digital overload, substance use and diet.

RECOVERY

The return to baseline. Without it, the same load does more harm.

ADAPTIVE CAPACITY

The reserve to adapt. A planned future measure.

BUILDINGBURDEN LOAD RECOVERY Load outruns recovery Time → Conceptual

MUDH™ Signals (self-report, passive, wearable and clinical data) → candidate MUDH™ Biomarkers for Load, Recovery and Capacity, validated against clinical reference measures.

From load to inflammation

How load, recovery and capacity become inflammation.

When recovery stays incomplete, stress systems can stay on, immune cells can tune out cortisol and low-grade inflammation can persist: a shared pathway to many chronic conditions.

Load ↑

Repeated demands

stress, poor sleep, isolation

Recovery ↓

Incomplete reset

body doesn't return to baseline

Capacity ↓

Reserve wears down

planned future measure

Stress systems stay switched on

HPA axis (cortisol) and sympathetic nervous system

Cortisol stops calming inflammation

glucocorticoid receptor resistance

Chronic low-grade inflammation

IL-6 · CRP · TNF-α

Feedback: inflammation disrupts sleep, mood and energy, adding load and slowing recovery

Where UPSTRIQ™ measures

Conceptual pathway based on McEwen 1998; Cohen et al. 2012; Slavich & Irwin 2014; Furman et al. 2019. Not a fixed sequence. MUDH™ Biomarkers for Load, Recovery and Capacity are planned.
Research Vault

The evidence behind what's upstream.

Peer-reviewed research behind each MUDH™ Vital and the allostatic load pathway.

  • ~50%greater likelihood of survival with stronger social relationships, across 148 studies.
  • ~11Mdeaths in 2017 linked to poor diet, more than any other risk.
  • ~23%higher coronary heart disease risk with job strain, across ~197,000 people.

33 references, a plain-language allostatic load primer and the key study for every MUDH™ Vital.

Explore the evidence →

Help us read further upstream.

Explore research partnerships
UPSTRIQ / Platform Platform

The preventive health intelligence layer.

One architecture connecting measurement, biomarkers, forecasting, intervention and follow-up.

Our platform: MUDHIVA™

Closed-loop architecture.

MUDHIVA™ is focused on leading the paradigm shift: moving from reactive care to proactive, personalized and preventive health.

5MUDH™ Dash
Closed loopMUDHIVA™
Conceptual illustration. Select a step to explore it.
  1. 1
    MUDH™ MeasurementUpstream, root-cause drivers of health, scored as the MUDH™ Index and MUDH™ Vitals.
  2. 2
    MUDH™ SignalsIntegrates passive, wearable and clinical data for longitudinal monitoring and digital biomarkers of Load, Recovery and Capacity.
  3. 3
    MUDH™ ForecastChronic disease-specific risk models for mental health, cardiometabolic disease, maternal health and other chronic disease conditions.
  4. 4
    MUDH™ NavigatorStratifies risk and connects people to early intervention.
  5. 5
    MUDH™ DashEnterprise, healthcare and payer dashboards, with patient tracking.

MUDH™ — Modifiable Upstream Determinants of Health

The MUDH™ Index scores 0 to 100; MUDH™ Vitals show which Vitals changed.

MUDH™ Vitals
  • Emotional healthmood · confidence · hope
  • Stress & recoveryload · reset · resilience
  • Digitalscreens · attention · routines
  • Connectionbelonging · isolation
  • Nutritionfuel · metabolic health
  • Movementactivity · fitness
  • Sleep & circadianrepair · rhythm
  • Substancealcohol · nicotine · other

Each MUDH™ instrument is validated for a specified population and use.

ASPEN™, the first validation study, is in process.*

*ASPEN™ is validating the MUDH™ scale for reliability and validity.

MUDH™ Signals

Measure continuous change.

MUDH™ Signals adds phone, wearable and clinical data to MUDH™ measurement, tracking change continuously against each person's own baseline, not only at visits.

Passive or wearable signal MUDH™ Vital from monthly check-in

Sleep regularity

Wearable · phone
62 index↓ 20 vs baseline
MUDH™ Vital · Sleep & circadian39 ↓ 12

Social connection

Phone · ePRO
53 index↓ 17 vs baseline
MUDH™ Vital · Connection71 ↓ 9

Mood & stress (MUDH™)

ePRO
57 score↓ 18 vs baseline
MUDH™ Vital · Emotional health78 ↓ 6

UPSTRIQ™ is developing proprietary MUDH™ candidate digital biomarkers, with planned studies to evaluate their validity for defined populations and intended uses.

Risk forecasting & dashboards

Forecast chronic disease risk.

Predictive models turn each person's trajectory into a disease-specific forecast for a defined outcome and time window, so care can start earlier.

UPSTRIQ™HEALTH JMMember J.M. · Adult preventive cohort Nov 2025 – Nov 2026 Illustrative · not patient data
New-onset hypertension · 12 mo
18%vs 9% in similar people
Marker shows similar-people rate
Depression worsening · 6 mo
24%vs 11% in similar people
Marker shows similar-people rate
Risk band
  1. Band 1 · Flourishing
  2. Band 2 · Stable
  3. Band 3 · Emerging Risk
  4. Band 4 · Elevated Trajectory · this person
  5. Band 5 · Critical Trajectory
Projected trajectory · MUDH™ Index
4050607080 Today −12 mo +6 mo Forecast range
Navigator next step

Care-team review recommended · sleep plan shared

Illustrative example. Names, values and forecasts are not patient data.

  • Disease-specific forecasts for intended populations and uses.
  • Status: planned. Displays above are illustrative.
Dashboards

Enterprise, healthcare and payer dashboards.

Built for the people who act on them, each with patient tracking over time.

Enterprise

Employers, universities, wellness programs

Healthcare

Clinicians and care teams

Payer

Health plans and payers

Patients also see their own results, trends and next steps. Dashboard images are concept designs.

Data & connectivity

Data & connectivity.

Building

Building now

  • Self-reported assessments (PRO/ePRO).
  • SMART on FHIR clinical application.
Planned

Planned capabilities

  • Phones and passive sensing.
  • Wearables.
  • Home monitoring.
  • Broader clinical record integration.
  • APIs and partner integrations.
Learning cycle

A controlled learning cycle.

01

Follow-up measurements

Repeat measurement after care.

02

Observed outcomes

What happened, recorded over time.

03

Performance evaluation

How instruments, biomarkers and models performed.

04

Controlled refinement

Updates validated before deployment.

All ages · all chronic diseases

Works across all ages and all chronic diseases.

One measurement layer and validation method, applied population by population.

Across chronic disease
Mental healthCardiometabolicNeurodevelopmentalAging & cognitionInflammatory

A new population or condition adds a validated forecast, not a new platform.

Products & development status

What we are building.

ProductWhat it doesCurrent statusValidationNext
MUDH™ instrumentsPRO/ePRO assessment and screening, eight VitalsCore instrument developed (versioned scoring)Validation study in process (ASPEN™)Population-specific instruments
MUDH™ MonitorTracks the MUDH Index and Vitals over timeBuilding—Expanded longitudinal views
MUDH™ SignalsMUDH™ Biomarkers for Load, Recovery and Capacity——Load, Recovery and Capacity
Risk forecastingDisease-specific AI/ML models——Models for priority applications
NavigatorRisk bands, alerts, clinical review and routing——Framework planned
DashboardsEnterprise, healthcare and payer viewsConcept designs; planned—Planned
IntegrationsSMART on FHIR, APIs, partner connectionsSMART on FHIR application—APIs and partner integrations
Integrated systemThe connected closed loop——Planned

Status as of October 2026.

Proprietary technology & IP

Proprietary technology & intellectual property.

  • Provisional patent applications filed.
  • Proprietary software, instruments and methods.
  • Trade-secret protection for confidential algorithms and methods.
  • Licensing opportunities for partners.
Platform foundations

Platform foundations.

HIPAA compliant

HIPAA-compliant infrastructure with consent and permitted-use controls.

Enterprise scalability

Cloud software designed to scale from pilot to enterprise.

Security

Role-based access, secure data exchange and de-identified research data.

API

API-ready, with a SMART on FHIR app for EHRs.

Security & data governance

Security & data governance.

  • Built on HIPAA-compliant infrastructure.
  • Role-based access controls.
  • Consent and permitted data use.
  • De-identification for research data.
  • Secure data exchange.

Integrate upstream intelligence.

Discuss a platform integration
UPSTRIQ / Solutions Solutions

One platform, four products.

Use each product alone or together, by availability and intended use.

Use cases

Use cases.

How each customer puts MUDHIVA™ to work.

Pharma & Research

Trial enrichment and monitoring

Identify participants on emerging risk trajectories and track change between study visits with MUDH™ Signals.

Enterprise

Workforce and student health

Employers and universities see upstream health trends early and connect people to support, with de-identified reporting.

Healthcare

Between-visit patient tracking

Care teams follow the MUDH™ Index, MUDH™ Vitals and risk forecasts between visits and act before patients deteriorate.

Payers

Risk stratification for care management

Health plans prioritize members for early outreach and prevention programs, designed to reduce avoidable acute care.

Government

Population and public health programs

Agencies and programs track upstream drivers across populations to target prevention where it is needed most.

Product 1 of 4

MUDH™ Measuring System

Measure the modifiable upstream determinants of health.

  • Assessment and screening for clinicians and health systems.
  • ePRO/PRO instruments for research and clinical trials.
  • MUDH™ Monitor longitudinal tracking for coaches, universities and prevention programs.
Outputs
MUDH™ Index · MUDH™ Vitals · trends
Users & uses
Clinicians, researchers, trial teams, coaches, universities
Status
Validation study in process
Access
Licensing; research and pilot access

Opportunities to pilot our MUDH™ are opening and ongoing.

Product 2 of 4

Longitudinal Signals & Digital Biomarkers

MUDH™ Signals: passive and clinical data that measure continuous change.

  • A proxy of daily health between visits, read against each person's own baseline.
  • For research, monitoring and partner platforms.
Outputs
Load, Recovery and Capacity signals
Users & uses
Researchers, pharma, technology partners
Status
Planned
Access
Development and validation partnerships
Product 3 of 4

Risk Forecasting

Predictive models that forecast chronic disease risk.

  • Defined outcomes and prediction windows.
  • Individual trajectories and changing risk.
  • Validated for each intended population and use.
Outputs
Disease-specific risk forecasts
Users & uses
Health systems, payers, care programs, researchers
Status
Planned
Access
Pilots and collaborative development
Product 4 of 4

Risk Stratification & Intervention

Navigator stratifies risk and connects people to the right response.

  • Five risk bands, alerts and clinical review.
  • Connection to validated online interventions.
  • API routing to external care partners.
  • Follow-up measurement and evaluation.
Outputs
Risk bands, alerts, routing, follow-up
Users & uses
Health systems, payers, employers, care programs
Status
Planned
Access
Pilots and collaborative development
Across all four products

Dashboards and integration, built in.

Dashboards

Enterprise, healthcare and payer views

Each includes patient tracking over time.

Integration

Fits partner systems

Licensing, APIs and a SMART on FHIR app. Partners plug in, not rebuild.

Priority applications

Three priority applications.

Where we start. See the need behind each on the home page.

Priority application

Adolescent Mental Health

Earlier recognition of mental health risk, and connection to care.

Products
MUDH™ Measuring System · Risk Forecasting · Risk Stratification & Intervention
Users
Health systems, schools, universities, pediatric and behavioral health teams
Status
Planned
Engage
Discuss this application →
Priority application

Pregnancy & Postpartum Health

Risk forecasting across pregnancy and postpartum, linked to intervention.

Products
All four products
Users
Obstetric and maternal care teams, payers, researchers
Status
Planned
Engage
Discuss this application →
Priority application

Cardiometabolic Health

Earlier recognition of cardiometabolic risk, and intervention, from upstream, daily-life and clinical data.

Products
All four products
Users
Health systems, payers, employers, device partners
Status
Planned
Engage
Discuss this application →
Ways to engage

Ways to engage.

LicensingResearch CollaborationIntegrationPilots
Our roadmap

Preliminary Product Roadmap: Priority applications

01

MUDH™ Measuring System

Tracking with the MUDH™ Index and MUDH™ Vitals.

02

Signals & biomarkers

Load, Recovery and Capacity biomarkers.

03

Risk forecasting

First disease-specific models in our three priority applications.

04

Stratification & intervention

Risk bands linked to validated online interventions and partner care.

05

Expand

More conditions, including cognitive and inflammatory, at every age.

Find the right solution.

Discuss a solution
UPSTRIQ / About About

Company, vision and people.

UPSTRIQ™ HEALTH is a preventive health intelligence company, combining upstream health measurement with wearable, smartphone and clinical data to forecast chronic disease risk and connect people to earlier intervention.

Who is behind this

The people, partners and standards bringing this to life.

Leadership

Experienced leadership

Leadership team

Experience across drug, diagnostics and device development, clinical research, data science and commercialization.

Led by a founder with 30+ years in drug, diagnostics and device development.*

  • 12+products launched
  • $22B+product revenue
  • $41B+exits

*Founder's prior-company career. Not UPSTRIQ figures.

Advisors

Scientific & commercial advisors

Clinical & Scientific Advisors and a Commercial Advisory Board guide evidence and adoption.

Our advisors

Rigor

Rigor & trust

COSMIN · V3 · TRIPOD+AI · predefined go/no-go gates · de-identified research data · SMART on FHIR · safeguards designed to support HIPAA requirements.

Validation standards

Where we are going

Our vision.

Vision

Make preventive health intelligence part of everyday care, enabling action before disease develops, function declines, or chronic illness worsens.

The Golden Gate Bridge and San Francisco Bay at sunset
San Francisco Bay Area · Photo: Mollie Moran / Unsplash
Location

Palo Alto, California.

UPSTRIQ™ HEALTH is a Delaware C corporation headquartered in Palo Alto, California, where healthcare, research and technology meet.

  • CompanyDelaware C corporation
  • Headquarters
    855 El Camino Real, Suite 13A #349
    Palo Alto, CA 94301
  • Connect with usconnect@upstriq-health.com
Leadership team

Leadership team.

Shilpa Parikh

Shilpa Parikh, MBA

Founder & CEO

30+ years in drug, diagnostics and device development. Launched 12+ products, generating $22B+ in revenue and $41B+ in exits at prior companies. Brings healthcare and technology together, with a BS in Computer Engineering from the University of Michigan and an MBA from Carnegie Mellon’s Tepper School of Business.

Joe Salazar

Joe Salazar

Head of Finance & Corporate Development

27+ years in corporate finance, strategic operations, fundraising and organizational growth, including supporting biotechnology companies such as Genentech and Relypsa. Builds the financial, operational and governance infrastructure for complex, multi-institutional programs.

Colin Lacey

Colin Lacey

Head of Data Management & Analytics

Senior technology product executive, previously Chief Product Officer at Alegion and EVP of Product at MTPV Power, with earlier leadership roles at Unisys, HP and Acer. Leads the data layer and passive-data implementation.

Nima Parikh, MBA

Nima Parikh, MBA

Head of Commercial & Strategy

Strategy and commercialization executive with 25+ years in growth, brand, innovation and market strategy, including senior roles at P&G and Nestlé and advisory work for IBM, AT&T, Huawei and Caesars Entertainment. Leads corporate strategy, commercialization and strategic partnerships.

TS HariGopal, MBA

TS HariGopal, MBA

Head of Platform Technology & AI

Technology executive with 30+ years leading digital transformation in life sciences: AI, data and analytics, cloud, cybersecurity and regulatory compliance. Senior technology roles at IGM Biosciences, Cytokinetics, Pharmacyclics/AbbVie and Johnson & Johnson.

Rupa Patel, MD, MPH

Rupa Patel, MD, MPH

Chief Medical Officer

Physician with 20+ years across internal medicine, infectious diseases, public health and implementation science, including work with the CDC, WHO and Washington University. Brings clinical rigor and implementation readiness to every program.

Advisors

Our advisors.

Clinical & Scientific Advisors

Scientific & clinical guidance

Arnaud Bastien, MD

Clinical & Scientific Advisor

Vice President, Global Program Lead, Bristol Myers Squibb · cardiovascular development

Gregory E. Miller, PhD

Clinical & Scientific Advisor

Louis W. Menk Professor of Psychology, Northwestern University · Co-Director, Foundations of Health Research Center

Prerna Chikersal, PhD

Scientific Advisor (AI/ML)

Senior AI Engineer, Databricks

Lauren Wallace, MS, EdS

Clinical Advisor (Mental Health)

Mental health therapist and behavioral interventionist

Gregory Serapio-Garcia, PhD

Clinical & Scientific Advisor

Computational Psychologist and AI Researcher

Commercial advisory board

Commercial advisory board.

Payer, market and commercial guidance.

Renee P. Tannenbaum, PharmD, MBA

Commercial Advisory Board

Head of Corporate Development, Bench International

Dean Erhardt, MBA

Commercial Advisory Board

Founder, President & CEO, D2 Solutions · former VP of Sales and Marketing, Express Scripts Specialty Pharmacy Benefits Management · prior roles at U.S. Healthcare and Cardinal Health

Christian Neckermann, MBA

Commercial Advisory Board

Co-Founder, FirstMileBio · Founder, Cogent Healthcare

Mike Petro

Commercial Advisory Board

Independent Biopharma Commercial Consultant · formerly Commercial Leadership Team, Cytokinetics

Kentaro Tomine, L.Ac., MTCM

Commercial Advisory Board

CEO, Blooming Peak Eastern Medical

Pilots

Pilot partnerships.

We are planning paid pilots with care-delivery partners, starting with 90-day programs that pair MUDH™ measurement with longitudinal monitoring. Pilot letters of intent have been received from four organizations.

Internships

Internships at UPSTRIQ.

Opportunities, eligibility, areas of contribution and how to apply.

Talk with our team.

Request a conversation
UPSTRIQ / Research Research

Research & validation.

How we develop and validate our proprietary technology, layer by layer.

Open the Research Vault →
Validation pathway

Our validation pathway.

Nothing advances until it clears its pre-set GO criterion.

  1. 1

    Validate MEASURE™

    Psychometrics, reliability, responsiveness.

    GO: ω ≥ 0.80 · ICC ≥ 0.70
  2. 2

    Validate SIGNAL™

    Feature stability, reference biology and clinical change.

    GO: ICC ≥ 0.70 + held-out association
  3. 3

    Validate FORECAST™

    Locked disease-specific models, calibration, external test.

    GO: ΔAUROC ≥ 0.05 or +NRI · calibration 0.8–1.2
  4. 4

    Validate the system

    Repeat measurement, reviewed alerts, intervention capture.

    GO: ≥70% repeat measurement + workflow completion

NO-GO means revise or stop. We do not market a failed claim.

Research programs & studies

Programs and status.

Status as of October 2026.

ProgramPopulationObjectiveStatus
MUDH™ measuring systemAdultsEvaluate PRO and ePRO reliability and validityValidation study in process (ASPEN™, October 2026)
Adolescent mental healthAdolescentsEarlier recognition of changing mental health and functioningPlanned
Pregnancy and postpartum healthPregnant and postpartum peopleEmerging risk of depression, anxiety, hypertensive disorders and gestational diabetesPlanned
Cardiometabolic healthAdultsEarlier recognition of changing cardiometabolic riskPlanned
Load and Recovery biomarkersAdultsDigital biomarkers of sustained load and recoveryPlanned
Research partnerships

Research partnerships.

We partner with academic, clinical and industry teams on every validation layer and on clinical evaluation.

UPSTRIQ / Who We Serve Who we serve

The right partnership for each audience.

Initial focus: care-delivery organizations with longitudinal prevention or chronic-condition programs, starting with virtual and specialty care.

Pharma & Research

Pharma & Research

  • Pharma and biotech companies
  • Academic researchers
  • Clinical trial teams
Need
Standardized upstream context and longitudinal outcomes.
Solution
MUDH™ Measuring System (ePRO/PRO); Longitudinal Signals & Digital Biomarkers (planned)
Application
ePRO/PRO, longitudinal research, biomarker development and model evaluation.
Engage
See the solution → · Supporting research →
Enterprise

Enterprise

  • Employers
  • Universities
  • Wellness and prevention groups
  • Technology and digital health firms
Need
Seeing the drivers of health before claims, absences or disengagement.
Solution
MUDH™ Measuring System; enterprise dashboards (planned)
Application
Measurement, monitoring and prevention programs.
Engage
See the solution → · Supporting research →
Healthcare

Healthcare

  • Care-delivery and virtual-care programs (initial focus)
  • Healthcare professionals
  • Health systems
Need
Risk builds between visits.
Solution
MUDH™ Measuring System; Risk Forecasting (planned); Risk Stratification & Intervention (planned)
Application
Longitudinal assessment, between-visit tracking, risk evaluation and connection to care.
Engage
See the solution → · Supporting research →
Payers

Payers

  • Health plans
  • Payers and insurers
  • Value-based care organizations
Need
Costs land downstream; risk builds between claims.
Solution
MUDH™ Measuring System; Risk Stratification & Intervention (planned); payer dashboards (planned)
Application
Member risk stratification, care management and value-based programs.
Engage
See the solution → · Supporting research →
Government

Government

  • Public health agencies
  • Medicaid and Medicare programs
  • Federal health and research agencies
Need
Earlier signals of chronic disease risk across populations.
Solution
MUDH™ Measuring System; Risk Stratification & Intervention (planned); dashboards (planned)
Application
Population prevention programs and program evaluation.
Engage
See the solution → · Supporting research →

Find the right partnership.

Find the right partnership
UPSTRIQ / Investors Investors

Investing in upstream health.

Capital strategy

What each source of capital accomplishes.

First commercial milestones are planned on the equity path and do not depend on grants.

Equity · seed round

Commercial path

  • Complete MUDH™ measurement validation.
  • Launch first paid pilots and monitoring.
  • Integrate wearables; begin Load and Recovery analytical validation.
  • Build commercial and implementation teams.
Non-dilutive · if awarded

Research acceleration

  • Larger biomarker and forecasting studies.
  • Clinical validation of forecasting models.
  • Integrated-system evaluation in care workflows.

Status: ARPA-H and NIH SBIR applications under review. No awards have been made.

Technology

Proprietary technology & IP.

Provisional patent applications filed; software, instruments and methods held as trade secrets.

Request an investor conversation.

Request an investor conversation
UPSTRIQ / Research Vault Research Vault

The evidence behind what's upstream.

The research behind MUDH™, the Modifiable Upstream Determinants of Health: key studies by Vital, an allostatic load primer and the full reference library.

UPSTRIQ publications: none yet. Results will be listed here as studies are reported.

MUDH™ Vitals

The evidence behind each MUDH™ Vital.

Each Vital is modifiable and linked in peer-reviewed research to chronic disease, mental health or mortality.

Emotional health

Optimism was associated with a 35% lower risk of cardiovascular events across ~230,000 people.

[22] Rozanski et al. · JAMA Netw Open, 2019

Read the study →

Social threat activates inflammation that can drive depressive symptoms. [9] Slavich & Irwin · Psychol Bull, 2014 · Read →

Stress & recovery

Job strain carried ~23% higher coronary heart disease risk across ~197,000 people.

[23] Kivimäki et al. · Lancet, 2012

Read the study →
Digital

More than 3 hours a day of social media was linked to later depression and anxiety in ~6,600 adolescents.

[24] Riehm et al. · JAMA Psychiatry, 2019

Read the study →
Connection

Stronger social relationships: ~50% greater likelihood of survival across 148 studies.

[13] Holt-Lunstad, Smith & Layton · PLoS Med, 2010

Read the study →
Nutrition

Poor diet was linked to ~11 million deaths in 2017, more than any other risk factor.

[25] GBD 2017 Diet Collaborators · Lancet, 2019

Read the study →
Movement

Physical inactivity accounts for 6–10% of several major chronic diseases and ~9% of premature deaths.

[26] Lee et al. · Lancet, 2012

Read the study →
Sleep & circadian

Both short and long habitual sleep are associated with higher mortality.

[27] Cappuccio et al. · Sleep, 2010

Read the study →
Substance

Alcohol is the leading risk factor for death and disability among people aged 15–49.

[28] GBD 2016 Alcohol Collaborators · Lancet, 2018

Read the study →
Pathway · Allostatic load

Higher allostatic load predicted later cardiovascular disease, decline and mortality in older adults.

[29] Seeman et al. · Arch Intern Med, 1997

Read the study →
Pathway · Inflammation

Inflammation-related diseases account for over half of deaths worldwide; chronic inflammation is linked to stress, sleep, diet, inactivity and isolation.

[30] Furman et al. · Nature Medicine, 2019

Read the study →
Primer

Allostatic load, explained.

2 MIN READ

The cumulative cost of repeated stress adaptation, and why it matters.

Your body is built to handle stress. Cortisol and adrenaline rise, the heart speeds up and energy is mobilized. This stability through change is called allostasis [1]; short term, it protects us [2].

The problem is repetition. When stress is frequent, prolonged or never switched off, the same systems wear us down. This cumulative cost is allostatic load [1][2]: the biological price of adapting, paid over years.

It can be measured by combining markers such as blood pressure, stress hormones, blood sugar, cholesterol and inflammation into one score. In the MacArthur studies of successful aging, this score predicted mortality and physical and cognitive decline better than any single marker [3]. Later reviews link it to cardiovascular, metabolic, cognitive and mental health outcomes [4][5].

It starts early. Childhood adversity is associated with higher allostatic load and age-related disease decades later [6]. Childhood stress appears to shape immune and stress responses for life [7].

So prevention must start upstream. Allostatic load builds long before diagnosis, and its drivers (chronic stress, poor sleep, isolation, diet, inactivity and substance use) are modifiable. The MUDH™ Vitals are designed to capture them. Load and Recovery, which are planned, are intended to show whether the body is resetting or falling behind, so change may be seen and acted on earlier.

Reference library

Reference library.

Filter, or search by author, topic or finding. Links open the original source.

  1. Stress & disease 6
  2. [2]
    Stress & disease

    McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med, 1998.

    Key finding: Stress mediators protect in the short term and damage over time.

    Read the study →
  3. [7]
    Stress & disease

    Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging. Psychol Bull, 2011.

    Key finding: Childhood stress becomes embedded in biology and shapes later chronic disease risk.

    Read the study →
  4. [8]
    Stress & disease

    Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA, 2007.

    Key finding: Chronic stress contributes to depression, cardiovascular disease and infection.

    Read the study →
  5. [12]
    Stress & disease

    Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol, 2018.

    Key finding: Reviews how chronic stress raises cardiovascular risk.

    Read the study →
  6. [20]
    Stress & disease

    Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the ACE Study. Am J Prev Med, 1998.

    Key finding: Early adversity tracked with adult disease and early death.

    Read the study →
  7. [23]
    Stress & disease

    Kivimäki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis. Lancet, 2012.

    Key finding: Job strain ~23% higher CHD risk across ~197,000 people.

    Read the study →
  8. Allostatic load 7
  9. [1]
    Allostatic load

    McEwen BS, Stellar E. Stress and the individual: mechanisms leading to disease. Arch Intern Med, 1993.

    Key finding: Introduced "allostatic load" as the cumulative cost of chronic stress adaptation.

    Read the study →
  10. [3]
    Allostatic load

    Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. PNAS, 2001.

    Key finding: A multi-system allostatic load score predicted mortality and decline better than single markers.

    Read the study →
  11. [4]
    Allostatic load

    Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev, 2010.

    Key finding: Reviews allostatic load biomarkers and their links to health and cognition.

    Read the study →
  12. [5]
    Allostatic load

    Guidi J, Lucente M, Sonino N, Fava GA. Allostatic load and its impact on health: a systematic review. Psychother Psychosom, 2021.

    Key finding: Links allostatic load to a broad range of physical and mental health outcomes.

    Read the study →
  13. [6]
    Allostatic load

    Danese A, McEwen BS. Adverse childhood experiences, allostasis, allostatic load, and age-related disease. Physiol Behav, 2012.

    Key finding: Connects early adversity to allostatic load and later age-related disease.

    Read the study →
  14. [21]
    Allostatic load

    Cohen S, Janicki-Deverts D, Doyle WJ, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. PNAS, 2012.

    Key finding: Chronic stress reduced immune cells' response to cortisol, so inflammation was not switched off.

    Read the study →
  15. [29]
    Allostatic load

    Seeman TE, Singer BH, Rowe JW, Horwitz RI, McEwen BS. Price of adaptation: allostatic load and its health consequences. MacArthur studies of successful aging. Arch Intern Med, 1997.

    Key finding: Higher allostatic load predicted later CVD, decline and mortality in older adults.

    Read the study →
  16. Inflammation 1
  17. [30]
    Inflammation

    Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med, 2019.

    Key finding: Inflammation-related diseases account for over half of deaths worldwide; chronic inflammation is linked to stress, sleep, diet, inactivity and isolation.

    Read the study →
  18. Mental health 6
  19. [9]
    Mental health

    Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull, 2014.

    Key finding: Social threat activates inflammation that can drive depressive symptoms.

    Read the study →
  20. [10]
    Mental health

    Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications. JAMA Psychiatry, 2015.

    Key finding: People with mental disorders lose an estimated 10 years of potential life on average.

    Read the study →
  21. [11]
    Mental health

    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005.

    Key finding: Half of all lifetime mental disorders begin by age 14.

    Read the study →
  22. [16]
    Mental health

    Centers for Disease Control and Prevention. Youth Risk Behavior Survey: Data Summary & Trends Report, 2013–2023. CDC, 2024.

    Key finding: 40% of high school students reported persistent sadness or hopelessness in 2023.

    Read the study →
  23. [22]
    Emotional health

    Rozanski A, et al. Association of optimism with cardiovascular events and all-cause mortality: a systematic review and meta-analysis. JAMA Netw Open, 2019.

    Key finding: Optimism was associated with a 35% lower risk of cardiovascular events across 15 studies and ~230,000 people.

    Read the study →
  24. [24]
    Mental health

    Riehm KE, Feder KA, Tormohlen KN, et al. Associations between time spent using social media and internalizing and externalizing problems among US youth. JAMA Psychiatry, 2019.

    Key finding: >3 h/day of social media linked to later depression and anxiety in ~6,600 adolescents.

    Read the study →
  25. Sleep 2
  26. [15]
    Sleep

    Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis. Biol Psychiatry, 2016.

    Key finding: Sleep disturbance associated with higher CRP and IL-6.

    Read the study →
  27. [27]
    Sleep

    Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis. Sleep, 2010.

    Key finding: Short and long habitual sleep both associated with higher mortality.

    Read the study →
  28. Connection 2
  29. [13]
    Connection

    Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med, 2010.

    Key finding: Stronger social relationships: ~50% greater likelihood of survival across 148 studies.

    Read the study →
  30. [14]
    Connection

    Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke. Heart, 2016.

    Key finding: Loneliness and isolation associated with higher CHD and stroke risk.

    Read the study →
  31. Nutrition 1
  32. [25]
    Nutrition

    GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017. Lancet, 2019.

    Key finding: Poor diet linked to ~11 million deaths in 2017, more than any other risk factor.

    Read the study →
  33. Movement 1
  34. [26]
    Movement

    Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide. Lancet, 2012.

    Key finding: Inactivity: 6–10% of several major chronic diseases, ~9% of premature deaths.

    Read the study →
  35. Substance 1
  36. [28]
    Substance

    GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016. Lancet, 2018.

    Key finding: Alcohol: leading risk factor for death and disability ages 15–49.

    Read the study →
  37. Measurement science 6
  38. [17]
    Measurement science

    Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol, 2010.

    Key finding: Defines the measurement properties UPSTRIQ™ validation is designed around.

    Read the study →
  39. [18]
    Measurement science

    Insel TR. Digital phenotyping: technology for a new science of behavior. JAMA, 2017.

    Key finding: Passive smartphone and sensor data can serve as continuous behavioral measures.

    Read the study →
  40. [19]
    Measurement science

    Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology, 2016.

    Key finding: Passive phone data can quantify behavior relevant to mental health.

    Read the study →
  41. [31]
    Measurement science

    Goldsack JC, Coravos A, Bakker JP, et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). npj Digit Med, 2020;3:55.

    Key finding: Defines the three-part V3 framework for showing that a digital measure is fit for its intended use.

    Read the study →
  42. [32]
    Measurement science

    FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016, updated.

    Key finding: Standard definitions of biomarker types and validation terms used by FDA and NIH.

    Read the study →
  43. [33]
    Measurement science

    Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ, 2024;385:e078378.

    Key finding: Reporting standard for clinical prediction models, including those built with machine learning.

    Read the study →

See the path. Shape what's next.

Request a briefing
UPSTRIQ / Contact Contact

Request a conversation.

connect@upstriq-health.com · 855 El Camino Real, Suite 13A #349, Palo Alto, CA 94301.

Request a briefing

Tell us about your population.

Bring one population, one outcome and one question. We'll discuss how upstream measurement could apply.

UPSTRIQ / About / Internships Internships

Learn where health begins.

Join UPSTRIQ™ HEALTH and help measure upstream health, track change through digital biomarkers and forecast risk early enough to intervene.

Internship areas

Where you could contribute.

Data science & machine learning

Build and evaluate models that turn digital biomarkers into risk forecasts.

Digital biomarkers & passive sensing

Use wearable and phone data to track change against a personal baseline.

Clinical & behavioral research

Support validation studies of the MUDH™ measuring system and its PRO/ePRO instruments.

Product & design

Shape how people and care teams see trajectories and forecasts.

Commercial strategy & partnerships

Map partners across payers, employers, health systems and life sciences.

Who should apply

Curious, rigorous and mission-driven.

Undergraduate and graduate students in computer science, data science, engineering, psychology, public health, medicine, design and business who care about prevention and take evidence seriously.

How to apply

Email your resume and a short note on your area to connect@upstriq-health.com, subject "Internship".

Contact us →

Contact UPSTRIQ.

Contact UPSTRIQ
UPSTRIQ / Privacy & data use Privacy & data use

Your data, handled with care.

How this website collects, uses and protects information. Last updated October 2026.

Last updated: October 2026UPSTRIQ™ HEALTH · 855 El Camino Real, Suite 13A #349, Palo Alto, CA 94301 · connect@upstriq-health.com

Scope

This policy covers the UPSTRIQ™ HEALTH website. Our assessment tools and research studies are governed separately by their own consent forms, data agreements and, where applicable, institutional review board (IRB) oversight.

Information you give us

When you request a briefing or email us, you share your name, organization, the type of organization you work with, your work email and your message. We use this only to respond, schedule a conversation and follow up on your request.

Information collected automatically

This website does not use cookies, analytics, advertising or tracking pixels. Like any website, the servers that deliver it may record standard technical logs, such as IP address, browser type, pages requested and time, to deliver and secure the site.

Third-party services and links

Our fonts load from Google Fonts, so Google receives your IP address and browser information when a page loads. Links to sources such as the CDC and NIH take you to sites governed by their own privacy policies.

What we do not do

We do not sell or rent personal information, and we do not share it for advertising.

Sharing

We share contact information only with service providers who help us operate our email and website, under confidentiality obligations; when required by law; or as part of a merger, financing or acquisition, subject to this policy.

Retention

We keep inquiry correspondence as long as needed to respond and to maintain ordinary business records. You can ask us to delete it at any time.

Health and research data

This website does not collect health information. Please do not send personal health information through the briefing form or by email. Data from our assessment tools and studies is collected only with consent and is handled under the study's consent terms and our agreements with clinical and research partners.

Children

This website is not directed to children under 13, and we do not knowingly collect their information. Studies involving adolescents are conducted with research partners under IRB oversight, with parental permission and adolescent assent.

Security

We use reasonable safeguards to protect the information you send us. No method of transmission over the internet is completely secure.

Your choices and rights

You can ask to see, correct or delete the information you have sent us. Depending on where you live, such as California, you may have additional rights. Email connect@upstriq-health.com with "Privacy" in the subject line, and we will respond within a reasonable time. We will not treat you differently for making a request.

Changes

If we change how this website handles information, we will update this page and the date above.

UPSTRIQ / Terms Terms of use

Terms of use.

Last updated October 2026.

Use of this website

This website provides general information about UPSTRIQ HEALTH and its work. By using it, you agree to these terms.

No medical advice

Content on this website is for information only. It is not medical advice and does not replace the judgment of a qualified clinician. UPSTRIQ assessment tools are investigational and are not FDA-cleared.

Intellectual property

The website, its content and the UPSTRIQ and MUDH™ names and marks belong to UPSTRIQ HEALTH. You may not copy or reuse them without permission, except as allowed by law.

Third-party links

Links to outside sources are provided for reference. We are not responsible for their content.

No warranties

The website is provided as is, without warranties of any kind, to the extent permitted by law.

Changes and contact

We may update these terms. Questions: connect@upstriq-health.com.